About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

Australia's S&P/ASX 200 rose more than 1% to 8,820.90 points.

2026-07-03

Australia's S&P/ASX 200 rose more than 1% to 8,820.90 points.

Other News
2026-07-03

Individual Stock News 1. Estun (02715.HK) plans to acquire 100% equity of Estun Coolcool. 2. Country Garden (02007.HK) reported contracted sales attributable to shareholders of approximately RMB 2.45 billion in June. 3. GAC Group (02238.HK) report

Individual Stock News 1. Estun (02715.HK) plans to acquire 100% equity of Estun Coolcool. 2. Country Garden (02007.HK) reported contracted sales attributable to shareholders of approximately RMB 2.45 billion in June. 3. GAC Group (02238.HK) reported vehicle sales of approximately 773,100 units in the first six months of the year, a year-on-year increase of 2.35%. 4. Hanstech-B (03378.HK) has entered into an AI drug development collaboration with TwinEdge Bioscience. 5. A subsidiary of China Power (02380.HK) entered into a RMB 219.9 million EPC contract for the construction of a desulfurization system. 6. China Shenhua (01088.HK): Unit 5 of the Dingzhou Phase III and Unit 5 of the Cangdong Phase III have passed 168 hours of trial operation. 7. China Technology Group (01725.HK): Unaudited operating revenue in June was approximately RMB 58.11 million, representing a year-on-year increase of approximately 103.54%. 8. Poly Property Group (00119.HK) issued a profit warning: It expects an interim loss attributable to owners of RMB 700 million to RMB 800 million, a reversal from profit to loss year-on-year. 9. Kuaishou (01024.HK): Beijing Keling will hold Keling AI-related assets and businesses; multiple investors have agreed to inject US$2 billion into Keling AI. 10. Hengrui Medicine (01276.HK): SHR-8068 injection, adebelimumab injection, and apatinib mesylate tablets will soon commence clinical trials. 11. CSPC Pharmaceutical Group (01093.HK): Entered into a collaboration, option, and licensing agreement with AstraZeneca for the development of siRNA drugs, with the agreement including potential sales milestone payments of up to US$1.2 billion.
2026-07-03

July 3 — The Beijing Stock Exchange said it has terminated the IPO review of Anhui Tangxing Equipment Technology Co. after the company submitted an application to withdraw its public offering and BSE listing documents.

July 3 — The Beijing Stock Exchange said it has terminated the IPO review of Anhui Tangxing Equipment Technology Co. after the company submitted an application to withdraw its public offering and BSE listing documents.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.